USFDA issues will take long: Ranbaxy

Font Size

Print

Feedback

Email

Discuss

Related Articles

Pfizer’s Handa is new MD of Wyeth IndiaLower forex losses put Ranbaxy back in the blackPfizer profit up 26% on job cutsPfizer forms policies to raise standards

New Delhi: Pharmaceuticals major Ranbaxy on Monday said it is in talks with the US Food and Drug Administration (USFDA) to sort out issues related to generic drugs but the matter is likely to take long to resolve.

“Issues with the USFDA will take long and cannot be resolved in a day and discussions with the FDA are going on,” Ranbaxy Laboratories chief executive officer Atul Sobti said here on the sidelines of the India Economic Summit.

Last year, the USFDA had banned 30 generic drugs produced at Ranbaxy’s plants at Poanta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh citing violation of good manufacturing practice.

Subsequently, Application Integrity Policy (AIP) was imposed on Poanta Sahib facility, which meant the company's drug applications were yet to be reviewed.

Sobti also said Ranbaxy’s proposed three-year strategy plan with Japanese Daiichi Sankyo will be a comprehensive one, including manufacturing tie-up and partnership in new chemical entity development. It will be announced by January-end next year, he added.

The plan is aimed at enhancing value of both the companies with major focus on branded drugs and its back end support.

Earlier this year, both the companies entered into an arrangement under which Ranbaxy would market the branded products from Daiichi Sankyo’s portfolio in regions where the Japanese firm did not have a strong presence.